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ScienceDirectLentiviruses have evolved to infect and replicate in a variety of
cell types in vivo whilst avoiding the powerful inhibitory
activities of restriction factors or cell autonomous innate
immune responses. In this review we offer our opinions on how
HIV-1 uses a series of host proteins as cofactors for infection.
We present a model that may explain how the capsid protein
has a fundamental role in the early part of the viral lifecycle by
utilising cyclophilin A (CypA), cleavage and polyadenylation
specificity factor-6 (CPSF6), Nup358 and TNPO3 to
orchestrate a coordinated process of DNA synthesis, capsid
uncoating and integration targeting that evades innate
responses and promotes integration into preferred areas of
chromatin.
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Introduction
Retroviruses are defined by their ability to integrate a
DNA copy of their genome into the host chromatin. In
order to achieve this, they must first reverse transcribe
(RT) their RNA genome into double stranded DNA and
then gain access to the nucleus. The majority of retrovirus
families are dependent upon mitosis to access the nuclear
compartment. In contrast, lentiviruses, such as human
immunodeficiency virus type-1 (HIV-1), have evolved to
traverse the nuclear pore complex (NPC) allowing repli-
cation in non-dividing cells such as macrophages. Whilst
the molecular details of reverse transcription and
integration have been well established, much remains§ This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution and reproduction in any medium, provided the original
author and source are credited.
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protects the reverse transcription complex (RTC), a pro-
cess called uncoating. In particular, the host cell cofactors
on which the virus depends have been the subject of
intense scrutiny of late, and as a result our understanding
is rapidly progressing. It is becoming evident that the
early interactions between host cofactors and the viral CA
are key in determining the path taken by the viral core,
and that these interactions influence downstream pro-
cesses. As further details become clear we propose that
this new knowledge will allow novel therapeutic inter-
ventions, and more effective use of lentiviruses as tools.
The role of CA in early infection
The timing of uncoating
Uncoating has been one of the most enigmatic aspects of
early HIV-1 infection and is defined as the loss of the CA
core from the RTC. Conflicts of size suggest that the
conical core must be lost before nuclear entry: the width
of the core is 50–60 nm, whereas the NPC pore diameter
is 30 nm, but the precise timing and mechanism of
uncoating remain undefined. Early biochemical analyses
of cores purified from newly infected cells suggested that
the HIV-1 CA core is unstable and lost soon after cell
entry [1,2]. This was interpreted as CA being dispensable
for subsequent viral processes. However, recent genetic
data suggest that CA stays associated with the virion for
longer [3]. The different models for disassembly stem in
part from the fact that biochemical assays measure what
happens to the majority of particles, most of which do not
successfully infect the cell, whereas genetic analyses can
be focused on the infectious particles only, for example,
by reading out infection through GFP expression [4].
Microscopy approaches have also led to conflicting con-
clusions, with some studies supporting cytoplasmic
uncoating, whilst others have suggested later, NPC
associated, uncoating [5,6–8].
A functional role for CA
Consistent with an important role for CA in the incoming
phase of the life cycle, several studies have functionally
linked reverse transcription and uncoating. An increasing
number of studies demonstrate that suppressing reverse
transcription delays uncoating, supporting a role for
reverse transcription in promoting uncoating [5,9,10].
Furthermore, certain CA mutants have defects in reverse
transcription [11,12]. Some authors have suggested that a
late role for CA, despite early uncoating, may be ration-
alised by partial CA uncoating in the cytoplasm. How-
ever, it is difficult to understand how partial uncoatingwww.sciencedirect.com
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the CA structure appears to be unattached to its contents,
and dependent on a lattice of CA-CA interactions [13].
However, it is becoming evident that mutations in CA can
influence events that occur downstream of the uncoating
event. HIV-1 CA has now been well established as a viral
determinant for nuclear entry and the ability to infect
non-dividing cells [14–16]. As discussed below, mutation
of CA also impacts on the use of downstream cofactors
including TNPO3, Nup358 and Nup153, all of which
influence integration site targeting [3,17,18]. CA is
therefore likely to also have consequences for expression
of the viral RNA/proteins due to its influence on the
provirus context within chromatin.
Host cofactors for nuclear entry
The fact that CA impacts on viral processes even after its
loss most likely results from influential interactions that
occur between the CA and host cofactors before the
uncoating process begins. How CA has such a central
role in the behaviour of HIV-1 is gradually being uncov-
ered by a wealth of literature surrounding the identifi-
cation and role of host proteins in this stage of HIV
infection. As our understanding of these data grows, so
it informs our understanding of basic viral and cellular
biology.
TNPO3/nucleoporins
In 2008 genome wide siRNA screens identified a large
number of putative host cofactors for HIV-1 infection
[19,20]. Amongst these were the karyopherin TNPO3,
also identified as an HIV-1 integrase interactor in a yeast-
2-hybrid screen [21], and NPC proteins Nup153 and
Nup358. Depletion of these proteins using RNA inter-
ference impaired HIV-1 infection [3,17,18,21–23],
and also impacted on integration site selection, with
integrated proviruses still being identified in genes but
in regions of lower gene density [24,25]. The precise
step of the viral life cycle at which these cofactors act has
been disputed [7,17,18,21,26–31]. This has been largely
due to conflicting measurements of the abundance of
2LTR circles, which are formed by components of the
non-homologous end joining pathway that are found
uniquely in the nucleus. Thus 2LTR circles are a
much-used marker for nuclear entry. However, two
recent studies elegantly demonstrated that 2LTR circle
PCR assays must use primer/probe sequences that actu-
ally span the LTR-LTR junction, or they can detect the
autointegrants that form as completed RT products back
up at the defective NPC and integrate into each other
[32,33]. The autointegrants in these studies were ident-
ified by sequencing the 2LTR PCR products. The use of
appropriately designed primers supports a nuclear entry
defect on depletion of TNPO3 [32].
How might HIV-1 CA influence nuclear entry? HIV-1 CA
is certainly capable of interacting with the NPC directlywww.sciencedirect.com by binding to the cyclophilin-like domain of Nup358
[7,18]. In this way Nup358 recruitment may tether a
reverse transcribing virion to the NPC and orchestrate
interaction with the nuclear transport machinery during
the uncoating process. The isolated Nup358 Cyp domain
has been shown to catalyse cis–trans isomerisation of the
G89-P90 bond in CA using NMR techniques [34] and
although it is irresistible to hypothesise that this manip-
ulation of CA has a role in controlling uncoating, direct
evidence remains elusive. Nup358 also possesses Ran
binding domains, and as such could play a role in the
regulation of RanGTP dependent nuclear import.
TNPO3, itself a RanGTP dependent nuclear import
protein, is a likely candidate for trafficking the virus
towards or through the NPC. TNPO3 is capable of
directly binding HIV-1 integrase (IN), but the import-
ance of this interaction to nuclear entry has been con-
troversial [21,22,35], not least because dependence
on TNPO3 has been genetically mapped to CA
[18,22,25,26]. However, interactions between CA
and Nup358 and CPSF6 could dictate the site of uncoat-
ing, either tethered to the NPC by Nup358 or in the
cytoplasm, and thus whether integrase has the opportu-
nity to encounter TNPO3. This possibility is supported
by the behaviour of HIV-1 CA mutants. For example, the
CPSF6 binding mutant CA N74D infects independently
of Nup358 and TNPO3 and has retargeted integration
preferences. Similarly, HIV-1 CA P90A infects indepen-
dently of CypA and Nup358 and also retargets integration
[3,18]. The nuclear basket component, Nup153, has
also been suggested to bind integrase, again with depen-
dence on Nup153 being mapped to CA [17,36]. More
recently, Nup153 has been shown to interact directly with
CA, binding the same pocket in CA which is bound by
CPSF6 [48].
CypA
It has been known for some time that cyclophilin A
(CypA) plays a role in HIV-1 infection, with CypA bind-
ing to an exposed loop on the surface of the CA protein
[37]. As a peptidyl-prolyl isomerase, CypA also catalyses
cis–trans isomerisation of CA but, as for Nup358, an
inability to separate binding and catalysis activities has
hindered studies into whether isomerisation contributes
to HIV-1 uncoating and infectivity [38,39]. Interaction
between CA and CypA can be blocked through the use of
cyclosporines or CA mutants G89V and P90A [40–42].
Despite a wealth of experimental data, understanding the
role of CypA in infection has been difficult, not least
because it varies between cell lines. New insight has
come from the observation that blocking the interaction
between CypA and CA relieves dependence on cofactors
Nup358 and TNPO3, and subsequently changes integ-
ration site targeting [18]. Importantly, cyclosporine (Cs)
can be used to target CypA without inhibiting Nup358
Cyp recruitment. This has suggested that interaction
between CypA and CA influences the course of HIV-1Current Opinion in Virology 2014, 4:32–36
34 Virus entryinfection even in circumstances where its manipulation
does not reduce infectivity. The mechanism by which
CypA influences the route of nuclear entry remains
intriguing but poorly understood.
CPSF6
Cleavage and polyadenylation specificity factor-6
(CPSF6) was initially described as an HIV-1 inhibitory
factor when a truncation of the murine variant was ident-
ified in a cDNA screen for restriction factors [3]. CPSF6
is primarily nuclear, but manipulation of the C-terminal
nuclear localisation signal results in its cytoplasmic
accumulation and inhibition of HIV-1 infection
[3,32,43]. Inhibition depends on direct recruitment
of CPSF6 by HIV-1 CA, and the co-crystal structure of a
CPSF6 derived peptide bound to CA revealed details of
the interaction [44]. Single point mutations in either the
truncated CPSF6 or CA are sufficient to ablate binding
(F321N and N74D respectively) and rescue infectivity
[3,28,44,45]. As mentioned above, the HIV-1 CA
N74D CPSF6 binding mutant has been highly informa-








A hypothetical model of cofactor mediated HIV-1 nuclear entry and integrati
recruited to the viral core. These interactions suppress premature reverse tr
allows HIV-1 to utilise the cofactors used by CPSF6 itself for nuclear entry, inc
CPSF6 nuclear entry releases the virus enabling DNA synthesis. Nup358 use
NPC, where appropriately orchestrated uncoating can expose the viral pre-in
In the absence of CypA or CPSF6 interaction, reverse transcription drives cy
retargeted integration. We envisage a complex process of carefully orchestra
that have evolved to allow evasion of innate immune sensors. The use of prot
30 end processing, allows HIV-1 to target transcriptionally active chromatin.
Current Opinion in Virology 2014, 4:32–36 cofactor. This mutant integrates with retargeted integ-
ration site preferences, essentially integrating into genes
randomly [18]. Importantly, this mutant also becomes
insensitive to depletion of Nup358 and TNPO3 [3] as
do other CPSF6 CA binding mutants [44]. We interpret
these results as showing that CPSF6 directs HIV-1 into a
particular pathway of nuclear entry that requires Nup358
and TNPO3 function. CPSF6 also appears to mediate
CA’s control of HIV-1 reverse transcription. The inter-
action between C-terminally truncated CPSF6 (delta
NLS CPSF6) and the viral core delays both RT and
uncoating [28,32]. Whilst initial reports of the capacity
of truncated CPSF6 to block RT have been conflicting
[3,28,45], a thorough investigation has determined that
these discrepancies can be mapped to CPSF6 exon
structure. CPSF6 mutants with a disrupted NLS but with
the natural exon structure are capable of blocking viral
DNA synthesis [43,46]. The mechanism of this inhi-
bition remains to be clarified, but the data support a
model in which CA recruitment of CPSF6 controls
reverse transcription and therefore uncoating, as well as
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on targeting. Shortly after entry into the cytoplasm CypA and CPSF6 are
anscription by a mechanism that remains unclear. CPSF6 recruitment
luding TNPO3. At the NPC CA recruits the cyclophilin domain of Nup358.
 allows docking or tethering of the reverse transcription complex to the
tegration complex for interaction with transport factors including TNPO3.
toplasmic uncoating, leading to Nup358 and TNPO3 independence and
ted simultaneous reverse transcription, uncoating and integration events
eins with a role in active transcription such as CPSF6, with its role in RNA
www.sciencedirect.com
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for CypA, depletion or over expression of CPSF6 does not
impact HIV-1 infection or replication in cell lines
[3,28,43]. However, given that both CypA and CPSF6
appear to influence the route of HIV-1 nuclear entry, we
propose that both of these proteins are important for HIV-
1 even though they do not always impact infectivity when
manipulated. This hypothesis is supported by the obser-
vation that neither the Cyp binding mutant HIV-1 CA
P90A, or the CPSF6 binding mutant HIV-1 CA N74D,
replicate in primary human macrophages [18,47] and
that manipulating CypA or CPSF6 interactions in these
cells causes HIV-1 to trigger innate immune DNA sensors
[46].
Conclusions
The mechanisms by which cofactors facilitate nuclear
entry are still largely hypothetical and, like all good
models, ours (Figure 1) is probably flawed, but testable.
We note that the interpretation of data is complicated by
the fact that the behaviours of NPC and nuclear transport
proteins are likely to be interconnected. Thus manipula-
tion of one, for example Nup358, has an impact on others,
for example, TNPO3. It can therefore be challenging to
establish whether a particular factor plays a direct role, or
whether it impacts infection by regulating other members
of a nuclear import pathway. However, it is reasonable to
suppose that HIV-1 has evolved to make use of a con-
nected series of proteins to optimally infect target cells
and access preferred regions of the genome. We hypoth-
esise that recruitment of CPSF6, a 30 end mRNA proces-
sing factor, is a way to target a pathway leading to the
peripheral regions of chromatin containing the active
genes that HIV-1 seeks. We imagine that defining
the details of such a complex situation will require the
collaboration of a variety of techniques including genetic,
microscopic and biochemical approaches to eventually
understand the molecular mysteries of lentiviral nuclear
import. We propose that cell type specificity of cofactor
use is important. Whilst HIV-1 infects several different
cell types in vivo it seems unlikely that the same cofactors
will be important for infection of distantly related cells,
for example, activated T cells versus terminally differ-
entiated macrophages. Thus it will be important to
remember that negative data can be difficult to interpret,
particularly if they appear to be cell type specific. We are
confident that eventually our greater understanding of the
processes of HIV-1 reverse transcription, uncoating and
nuclear transport will be fundamental to our ability to
manipulate infection both therapeutically and exper-
imentally.
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